RE:RE:OVs improve cancer immunotherapy by reprogramming TMEYes we all know pela works, remodels microevironment converts macrophages from m1 to m2, etc etc, no denying it. How do you know that this will be the preferred immunotherapy option used in the clinic? There's dozens of immunotherapies presently in development not to mention countless targeted therapies. CLTA-4 is rather promising in GI, numerous others including an ongoing collaboration between Roche/Tencentriq and Lokon (engineered oncolytic virus). I believe your view is a bit myopic noteable but if there's something you know to address this question then by all means share it.